Adoption stalled because the test is doubted, not because it is unknown.
Why sustained use plateaued, the one constraint to move first, and where to point the capital already committed. The first move is ready to start now.
An illustrative worked engagement follows. Meridian Diagnostics is fictitious, created to model the deliverable. It is not a client, and every figure is invented for illustration.
Meridian Diagnostics
A cleared point-of-care test that tells a clinician, during the visit and in about ten minutes, whether a respiratory infection is bacterial or viral.
The situationEstablished, stalled
The stallBought, then set down
Intended usersPrimary and urgent-care clinicians
The diagnosis, in one line
Clinicians know the test and it fits the visit. What holds adoption back is belief: they do not yet trust a viral result enough to withhold the antibiotic, so testing never changes the decision and never becomes routine.
Part one · The Adoption Read
Where adoption breaks, and why
Follow one hundred sites that bought the analyzer. Awareness, trial, and fit hold. Adoption falls away later, at a single step: letting the result change what gets prescribed.
The adoption cascade
Share of placed sites reaching each step of real use (illustrative).
Awareness, trial, and fit hold. Adoption collapses at the clinical decision: a viral result rarely changes the prescription, so the test stops being worth running and never becomes routine.
Where the system breaks
Not at awareness, purchase, or workflow. The break is inside the visit, at the moment of decision, when a viral result should stay the prescription and does not.
The mechanism is evidentiary. Clinicians do not yet trust the result enough to withhold the antibiotic, so they test and prescribe anyway. A test that does not change the decision is not worth repeating, and routine use never forms.
Which barrier binds
The Read sorts every stall into three. This is a state, not a grade.
Awareness
Not limiting
Clinicians know the test and when it applies.
Trust
Primary barrier
The result is not yet believed enough to change practice.
Usability
Not limiting
It runs inside the visit with no new steps.
The constraint that must move first
Evidentiary Trust. Clinicians have seen the evidence and do not yet believe it is strong enough to change practice.
Move it and the rest become reachable. A second Trust complication, the institutional kind (no guideline mandate, patchy coverage), is real but secondary, and is carried as a protected workstream rather than moved first.
The binding constraint, inside Trust
Trust has more than one kind. Capital goes to the one that must move first, not to Trust in general.
Evidentiary TrustMoves first
Institutional TrustCarried, second
Reputational TrustNot limiting
Relevance and fitNot limiting
The evidence, and its limits
What the evidence already shows
What sites do
Placement and awareness high; repeat testing per site low and flat.
What clinicians say
The reason given is doubt about acting on the result, not awareness or fit.
What they prescribe
Antibiotics still written alongside a viral result.
What still must be tested
The core bet
Whether independent, practice-based evidence actually shifts prescribing at scale. Being commissioned now.
The secondary
Whether coverage and guidelines are a real blocker in some segments, or only downstream of the evidence.
The spread
Whether the pattern holds as strongly in urgent care as in primary care.
Why we believe the diagnosis. Three independent vantages, what sites do, what clinicians say, and what they prescribe, converge on the same decision point. The diagnosis is triangulated, not a single data point read too far.
"I ran the test. I still wrote the script."
What this prevents
The trap this read avoids
The Awareness Default
Flat usage looks like a marketing problem, so the reflex is to spend on visibility. Awareness was never the constraint. That spend would broadcast a credibility gap wider, not close it. Naming the barrier redirects the money before it is committed.
Part two · The Adoption Sprint
Where the committed capital moves
The Sprint points the capital already committed at the constraint that must move first, with the slowest-to-pay-off workstream starting immediately.
The capital reallocation
Same money, aimed at the barrier that actually binds.
Reference sites run in the open; plain evidence materials for the decision moment.
Owner
Medical affairs and field, jointly.
Signal it is working
Clinician talk shifts from "does it work" to "when do I rely on it".
What waits
Territory expansion stays parked.
TurnsDays sixty to ninety
First move
Carry early evidence into the coverage and guideline track.
Owner
Market access, behind medical affairs.
Signal it is working
Repeat testing climbs where the evidence landed, not where reps visited.
What waits
Scale visibility only after evidence is persuading.
Read adoption again at ninety days. The check is not "did we spend the money" but "did repeat use move where the evidence landed". If it moved, the constraint is loosening. If it did not, the read is re-run before more capital follows.
How to read this. The Adoption Read is a diagnosis of what constrains adoption now, drawn from evidence, not a forecast. It names one binding constraint and sequences a real second behind it. The analysis behind the read stays behind it: this report shows barrier level and plain language by design. The cascade shows behavioral use data, not a diagnostic score. Meridian Diagnostics is fictitious and the figures are illustrative.